LinkedIn Icon
September 18-20, 2018
Boston, MA
* Please Note Change In Venue

 

Morning Workshops
Tuesday September 18

09.00 - 12.00
Workshop A: Blood-Brain Barrier Crossing Biologics: Current Status, Future Potential, & Challenges in Developing These Therapeutics?
Workshop Leader: Krzysztof Wicher, Principal Scientist & Group Leader, Ossianix

Developing blood-brain barrier (BBB) crossing therapeutics is challenging, but the potential rewards for success are huge, given the unmet need currently in a range of neurological diseases. An increasing amount of evidence suggests that by using efficient delivery methods such as Trojan-horse shuttles bispecific antibodies and other biologics can effectively cross the BBB, providing an interesting and novel application for these technologies.

Attend this workshop to gain valuable insights into:

  • Diseases of CNS that can be addressed by BBB-crossing bispecific therapeutics
  • Challenges faced when developing bispecific products to cross the BBB

The current landscape of the field: How advanced are BBB-crossing bispecifics and what are most promising strategies?

Krzysztof Wicher, Principal Scientist & Group Leader, Ossianix

09.00 - 12.00
Workshop B: Investigating Immune Modulation Through Bispecifics – How Can We Select Rational Designs?
Workshop Leader: Paul Moore, VP, Cell Biology & Immunology, MacroGenics

Multispecific formats clearly demonstrate opportunities to achieve a greater efficacy than combinations of individual mAbs in engaging the immune system, including targeting checkpoint modulating targets. Investigating the underlying biology of the indication and how designs can incorporate this is essential in establishing  target combinations to create effective immuno-oncology therapeutics.

Addressing the key challenge of the developing rational designs, this workshop will:

  • Investigate our mechanistic understanding of checkpoint inhibition to guide future targeting strategies
  • Share how bispecifics can add most value in modulating the immune system
  • Explore case studies detailing the synergistic effects of bispecific targeting

Paul Moore, VP, Cell Biology & Immunology, MacroGenics

Afternoon Workshops
Tuesday September 18

13.00 - 16.00
Workshop C: Investigating Approaches to Enable the Patient’s Body to Synthesise Bispecific Constructs by Administering DNA or mRNA Encoding the Therapeutic
Workshop Leader: Daniel Hofmann, Scientist, BioNTech Workshop Leader: Christine Engeland, Cancer Researcher, National Center for Tumor Diseases

The clinical development of novel bispecific approaches has no doubt been hindered by a variety of developability and delivery challenges. Innovative novel approaches aim to address this issue by administering mRNA or DNA encoding the bispecific construct, enabling the patient’s body to produce the therapeutic.

This workshop will provide an in-depth analysis of these approaches, shedding light on issues such as:

  • The unique challenges posed by developing and administering mRNA or DNA encoding bispecifics
  • Understanding the true benefits and future applications of this approach

Investigating preclinical evidence supporting these approaches and the issues that still need to be overcome

Daniel Hofmann, Scientist, BioNTech

Christine Engeland, Cancer Researcher, National Center for Tumor Diseases

13.00 - 16.00
Workshop D: Bioanalytical Strategy for Bispecifics: Beyond Classical PK & Immunogenicity Assessment
Workshop Leader: Dragan Grabulovski, CEO & Founder, Grabulovski Consulting Services Workshop Leader: Wibke Lembke, Associate Director Development, Covagen

Analyzing anti-drug-antibody (ADA) responses and the integrity of your bispecific format is of paramount importance in the preclinical and clinical development of any bispecific antibody and the selection of the right bioanalytical tools to address the question you would like to answer is a key consideration of this process.

Attend this workshop and:

  • Evaluate key considerations when assessing the bioanalytical strategy
  • Compare the pros and cons of different ADA assays

Discuss different pharmacokinetic assays

Dragan Grabulovski, CEO & Founder, Grabulovski Consulting Services

Wibke Lembke, Associate Director Development, Covagen